[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422000":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":33,"responsibleParty":47,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects with earlier PCR-proven COVID-19 and\u002For serum anti-SARS-CoV-2 antibodies",null,"Patients that require a medically indicated pulmonary resection.",[13],"Diagnostic Test: Lung biopsy",{"label":15,"type":10,"description":11,"interventionNames":16},"Subjects WITHOUT earlier PCR-proven COVID-19 and\u002For serum anti-SARS-CoV-2 antibodies",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","Lung biopsy","Biopsy of residuary material from a medically indicated pulmonary resection",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Laurens J Ceulemans, MD, PhD","UZ Leuven","PRINCIPAL_INVESTIGATOR",[29],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+ 32 16 34 34 25","laurens.ceulemans@uzleuven.be",[34],{"facility":26,"status":35,"city":36,"state":10,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Leuven","3000","Belgium",{"type":40,"coordinates":41},"Point",[42,43],4.70093,50.87959,{"lat":43,"lon":42},[46],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100422000",false,"NCT04775134","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma","REASSURE","Inclusion Criteria:\n\n* Patient requires medically indicated pulmonary resection\n* Informed consent\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\u002FCOVID-19\n* No informed consent","ALL","18 Years",{"count":59,"type":60},75,"ESTIMATED","OBSERVATIONAL","The aim of this study is to confirm or rule out the residual presence and viability of SARS- CoV-2 in the respiratory tract and lung parenchyma of patients previously infected with SARS-CoV-2.\n\nPresence and viability of SARS-CoV-2 in lung tissue will be assessed with reverse transcriptase-polymerase chain reaction (PCR) and viral culture. The histological location of residual SARS-CoV-2 will be determined with fluorescence immunohistochemistry and single molecule fluorescence in situ hybridization, targeting viral proteins and RNA respectively.",[64],"Covid19","2024-07-01",{"date":67,"type":68},"2024-07-03","ACTUAL",{"date":70,"type":68},"2021-01-31",{"date":72,"type":60},"2025-12-31",{"name":5,"class":6},1]